| Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer S Chan, ME Scheulen, S Johnston, K Mross, F Cardoso, C Dittrich, ... Journal of Clinical Oncology 23 (23), 5314-5322, 2005 | 526 | 2005 |
| The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression S Vonlanthen, J Heighway, HJ Altermatt, M Gugger, A Kappeler, ... British journal of cancer 84 (10), 1372-1376, 2001 | 388 | 2001 |
| Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer MM Borner, P Schöffski, R De Wit, F Caponigro, G Comella, A Sulkes, ... European Journal of Cancer 38 (3), 349-358, 2002 | 360 | 2002 |
| Oral capecitabine as an alternative to iv 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial W Scheithauer, J McKendrick, S Begbie, M Borner, WI Burns, HA Burris, ... Annals of Oncology 14 (12), 1735-1743, 2003 | 327 | 2003 |
| Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized … AD Roth, N Fazio, R Stupp, S Falk, J Bernhard, P Saletti, D Köberle, ... Journal of Clinical Oncology 25 (22), 3217-3223, 2007 | 311 | 2007 |
| Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma AD Roth, R Maibach, G Martinelli, N Fazio, MS Aapro, O Pagani, R Morant, ... Annals of oncology 11 (3), 301-306, 2000 | 305 | 2000 |
| Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer J Carmichael, T Popiela, D Radstone, S Falk, M Borner, A Oza, ... Journal of clinical oncology 20 (17), 3617-3627, 2002 | 300 | 2002 |
| A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with … JR Hecht, T Trarbach, E Jaeger, J Hainsworth, R Wolff, K Lloyd, G Bodoky, ... Journal of Clinical Oncology 23 (16_suppl), LBA3-LBA3, 2005 | 250 | 2005 |
| Phase II study of capecitabine and oxaliplatin in first-and second-line treatment of advanced or metastatic colorectal cancer MM Borner, D Dietrich, R Stupp, R Morant, H Honegger, M Wernli, ... Journal of clinical oncology 20 (7), 1759-1766, 2002 | 209 | 2002 |
| First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after … M Borner, M Bacchi, A Goldhirsch, R Greiner, F Harder, M Castiglione, ... Journal of clinical oncology 12 (10), 2071-2077, 1994 | 207 | 1994 |
| High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel D Crivellari, O Pagani, A Veronesi, D Lombardi, F Nole, B Thürlimann, ... Annals of oncology 12 (3), 353-356, 2001 | 160 | 2001 |
| Mitomycin C induces apoptosis and caspase-8 and-9 processing through a caspase-3 and Fas-independent pathway F Pirnia, E Schneider, DC Betticher, MM Borner Cell Death & Differentiation 9 (9), 905-914, 2002 | 154 | 2002 |
| Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors D BOHLEN, M BORNER, RW SONNTAG, MF FEY, URSE STUDER The Journal of urology 161 (4), 1148-1152, 1999 | 147 | 1999 |
| Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis M Scholz, M Zehender, GN Thalmann, M Borner, H Thöni, UE Studer Annals of oncology 13 (1), 121-124, 2002 | 146 | 2002 |
| Answering patients' needs: oral alternatives to intravenous therapy M Borner, W Scheithauer, C Twelves, J Maroun, H Wilke The oncologist 6, 12-16, 2001 | 144 | 2001 |
| Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical … M Borner, D Koeberle, R Von Moos, P Saletti, D Rauch, V Hess, A Trojan, ... Annals of oncology 19 (7), 1288-1292, 2008 | 136 | 2008 |
| Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression S Vonlanthen, J Heighway, MP Tschan, MM Borner, HJ Altermatt, ... Oncogene 17 (21), 2779-2785, 1998 | 134 | 1998 |
| Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3 MM Borner, CE Myers, O Sartor, Y Sei, T Toko, JB Trepel, E Schneider Cancer research 55 (10), 2122-2128, 1995 | 134 | 1995 |
| PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2 S Frese, F Pirnia, D Miescher, S Krajewski, MM Borner, JC Reed, ... Oncogene 22 (35), 5427-5435, 2003 | 129 | 2003 |
| Internucleosomal DNA fragmentation in gerbil hippocampus following forebrain ischemia Y Sei, DKJE Von Lubitz, AS Basile, MM Borner, RCS Lin, P Skolnick, ... Neuroscience letters 171 (1-2), 179-182, 1994 | 127 | 1994 |
